α-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia

Pharmacology

Volumn 65, Issue 3, 2002, Pages 119-128

  Thiyagarajan, M ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Adrenoceptor antagonists; Benign prostate hyperplasia; Lower urinary tract symptoms

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 3 [3 [4 [4 FLUORO 2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 5 METHYL 1H PYRIMIDINE 2,4 DIONE; 3 [N [2 (4 HYDROXY 2 ISOPROPYL 5 METHYLPHENOXY)ETHYL] N METHYLAMINOMETHYL] 4 METHOXY 2,5,6 TRIMETHYLPHENOL; 5 CHLORO N [2 (2 CYCLOPROPYLMETHOXYPHENOXY)ETHYL] ALPHA,ALPHA DIMETHYL 1H INDOLE 3 ETHANAMINE; 5 METHYL 3 [3 [4 [2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 1H PYRIMIDINE 2,4 DIONE; 5 METHYLURAPIDIL; 7 CHLORO 3,4,5,6 TETRAHYDRO 4 METHYL 2 VINYLTHIENO[4,3,2 EF][3]BENZAZEPINE; 8 [3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ANTIANDROGEN; BETA ADRENERGIC RECEPTOR; DOXAZOSIN; ENDOTHELIN RECEPTOR; HERBACEOUS AGENT; INDORAMIN; KDM 3213; NAFTOPIDIL; NIGULDIPINE; PHENOXYBENZAMINE; PRAZOSIN; RECEPTOR SUBTYPE; RWJ 38063; SEROTONIN RECEPTOR; SL 890591; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; Z 350; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MUSCLE CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; REVIEW; SMOOTH MUSCLE TONE; TREATMENT OUTCOME; URINARY TRACT DISEASE; URINARY TRACT OBSTRUCTION; MALE; METABOLISM;

ADRENERGIC ALPHA-ANTAGONISTS; HUMAN; MALE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA; HUMANS;

EID: 0036016946     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058037     Document Type: Review

References (81)

1. The development of human benign prostatic hyperplasia with age
2. Benign prostatic hyperplasia in an unselected community-based population: A survey of urinary symptoms, bothersomeness and prostatic enlargement
3. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia
4. Gross and light microscopic features of the pelvic plexus in the rat
5. 1 adrenergic receptors in human benign prostatic hyperplasia
6. 3H] rauwolscine
7. Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate
8. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate
9. In vitro characterization of the alpha-adrenoceptors in human prostate
10. Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype
11. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation
12. Pharmacological characterization of alpha-1-adrenoceptor subtypes in the human prostate: Functional and binding studies
13. Characterization of alpha-1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation
14. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate
15. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate
16. Characterization of alpha-1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man
17. The alpha-1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype
18. 1-adrenoceptor subtypes in rat aorta and prostate
19. Human alpha-2-adrenergic receptor subtype distribution: Widespread and subtype-selective expression of alpha 2C10, alpha 2C4, and alpha 2C2 mRNA in multiple tissues
20. 1-adrenoceptors
21. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: Implications for adrenoceptor classification
22. 1A-adrenoceptor?
23. Pharmacological subclassification of alpha-1-adrenoceptors in vascular smooth muscle
24. 1-adrenoceptor classification
25. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia
26. Benign prostatic hyperplasia: A stromal disease (in German)
27. Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis
28. Alpha-1 adrenoceptors in human prostate: Characterization and alteration in benign prostatic hypertrophy
29. Quantitation of alpha-1 and beta-adrenergic receptor densities in the human normal and hypertrophied prostate (in Japanese)
30. Quantitative analysis of adrenergic alpha-1 and alpha-2 receptors in human prostatic urethral tissue
31. Autonomic receptors in human prostate adenomas
32. Quantification and distribution of alpha-1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue
33. Distribution of beta-3-adrenoceptor mRNA in human tissues
34. A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia
35. 2 receptors in serotonin-induced contraction of rat prostate: Autoradiographical and functional studies
36. The effects of a new serotonin receptor antagonist (ketan-serin) on lower urinary tract function in patients with prostatism
37. Endothelin-1 in the human prostate: Tissue levels, source of production and isometric tension studies
38. Endothelin receptors and their cellular signal transduction mechanism in human cultured prostatic smooth muscle cells
39. Endothelin receptor in benign prostatic hyperplastic cells: Binding and functional studies
40. Mitogenic activity of endothelin on human cultured prostatic smooth muscle cells
41. Endothelin receptors in testosterone-induced prostatic hypertrophy in rats
42. Endothelin receptor density in human hypertrophic and nonhypertrophic prostate tissue
43. Identification of endothelin receptors in normal and hyperplastic human prostate tissues
44. Decreased contractile effect of endothelin-1 on hyperplastic prostate
45. Benign prostatic hypertrophy affects the endothelin receptor density in the human urinary bladder and prostate
46. Androgen receptor transcript level in benign hypertrophy and carcinoma of the human prostate
47. The results of double castration in hypertrophy of the patents
48. Effect of orchiectomy on the alpha adrenergic contractile response of dog prostate
49. The pathogenesis of benign prostatic hyperplasia
50. Effects of estradiol on norepinephrine-induced contraction, alpha adrenoceptor number and norepinephrine content in the female rabbit urethra
51. Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17-beta-estradiol
52. Placebo-controlled double-blind study to test the efficacy of the aromatase inhibitor ata-mestane in patients with benign prostatic hyperplasia not requiring operation
53. Steroid 5 alpha-reductase 2 deficiency
54. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck
55. Effects of phenoxybenzamine hydrochloride on canine lower urinary tract: Clinical implications
56. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia
57. Micturition in conscious rats with and without bladder outlet obstruction: Role of spinal alpha-1-adrenoceptors
58. Alpha-1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia
59. The clinical development of a 5-alpha-reductase inhibitor, finasteride
60. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: Evidence for its efficacy from studies with mepartricin
61. 1-adrenoceptors in vitro
62. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients
63. Treatment of chronic prostatitis and prostatodynia with pollen extract
64. Treatment of benign prostatic hyperplasia with phytosterols
65. Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate
66. Characterization and localization of prostatic alpha-1-adrenoceptors using radioligand receptor binding on slide-mounted tissue section
67. Pharmacologic characterization of CHIR 2279, an N-substituted glycine peptoid with high-affinity binding for alpha-1-adrenoceptors
68. Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH)
69. Evaluation of the pharmacological selectivity profile of alpha-1-adrenoceptor antagonists at prostatic alpha-1-adrenoceptors: Binding, functional and in vivo studies
70. Effects of tamsulosin metabolites at alpha-1-adrenoceptor subtypes
71. Different subtypes of alpha-1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053
72. KMD-3213, a novel, potent, alpha-1a-adrenoceptor-selective antagonist: Characterization using recombinant human alpha-1-adrenoceptors and native tissues
73. Pharmacological options in the treatment of benign prostatic hyperplasia
74. 1A-adrenoceptor-selective antagonists
75. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): Role of the alpha-1L adrenoceptor in tissue selectivity
76. Comparative study on alpha-1-adrenoceptor antagonist binding in human prostate and aorta
77. An investigation of the uroselective properties of four novel alpha(1a)-adrenergic receptor subtype-selective antagonists
78. Subtype selectivity of a new alpha-1-adrenoceptor antagonist, JTH-601: Comparison with prazosin
79. 1a-adrenergic receptor antagonists
80. 1-adrenoceptor antagonistic and steroid 5-alpha-reductase inhibitory actions
81. Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery